BioCardia (NASDAQ:BCDA) is a pioneering company in the development of regenerative biologic therapies to treat cardiovascular diseases, focusing primarily on heart failure and acute myocardial infarction. Their innovative approach includes a portfolio of cell therapy products and the Helix Biotherapeutic Delivery System, designed for precision delivery of biologics directly to the heart. A key objective for BioCardia is advancing their clinical programs, notably the CardiAMP and CardiALLO cell therapy trials, which aim to improve patient outcomes and redefine the standard of care in cardiovascular medicine. Through rigorous research and development, BioCardia strives to unlock the potential of regenerative medicine for cardiac patients worldwide, demonstrating a commitment to pushing the boundaries of medical science for better health outcomes.